Cyclopamine

For research use only. Not for use in humans.

目录号：S1146 别名： 11-deoxojervine 中文名称：环巴胺

CAS No. 4449-51-8

Cyclopamine (11-deoxojervine)是一种特异性Hedgehog (Hh)信号通路拮抗剂，作用于Smoothened (Smo)，在TM3Hh12细胞中IC50为46 nM。

规格

价格

库存

购买数量

5mg	RMB 1227.56	现货
25mg	RMB 3037.37	现货
50mg	RMB 3833.48	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Cyclopamine发表文献94篇：

Nature, 2021, 10.1038/s41586-021-03703-z

PubMed: 34234347 ( click the link to review the publication )

Nature, 2015, 10.1038/nature14325

PubMed: 25938716 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2021, 118(29)e2101783118

PubMed: 34230098 ( click the link to review the publication )

Cancer Res, 2021, canres.0198.2021

PubMed: 34167949 ( click the link to review the publication )

Cancers (Basel), 2021, 13(3)418

PubMed: 33499351 ( click the link to review the publication )

Cell Death Dis, 2021, 12(5):459

PubMed: 33966040 ( click the link to review the publication )

Cell Death Dis, 2021, 12(5):495

PubMed: 33993198 ( click the link to review the publication )

J Cell Mol Med, 2021, 10.1111/jcmm.16313

PubMed: 33507617 ( click the link to review the publication )

Cancer Med, 2021, 10.1002/cam4.4018

PubMed: 34076346 ( click the link to review the publication )

Molecules, 2021, 26(9)2607

PubMed: 33946996 ( click the link to review the publication )

Oncol Lett, 2021, 21(4):295

PubMed: 33732371 ( click the link to review the publication )

Can J Physiol Pharmacol, 2021, 10.1139/cjpp-2020-0588

PubMed: 33617370 ( click the link to review the publication )

J Orthop Surg Res, 2021, 16(1):160

PubMed: 33637095 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2021, 62(2):33

PubMed: 33616621 ( click the link to review the publication )

Nat Commun, 2020, 11(1):44

PubMed: 31896750 ( click the link to review the publication )

Cell Rep, 2020, 21;31(3):107521

PubMed: 32320667 ( click the link to review the publication )

Int J Cancer, 2020, 7

PubMed: 32383186 ( click the link to review the publication )

Stem Cell Reports, 2020, S2213-6711(20)30192-2

PubMed: 32589876 ( click the link to review the publication )

J Clin Endocrinol Metab, 2020, dgaa656

PubMed: 32936899 ( click the link to review the publication )

Stem Cell Res Ther, 2020, 11(1):488

PubMed: 33198821 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 20;2020:1868764

PubMed: 32377291 ( click the link to review the publication )

Proc Biol Sci, 2020, 287(1935):20192939

PubMed: 32933441 ( click the link to review the publication )

Chemosphere, 2020, 6;254:126709

PubMed: 32348926 ( click the link to review the publication )

Front Cell Neurosci, 2020, 14:575690

PubMed: 33343302 ( click the link to review the publication )
Int J Mol Sci, 2020, 21(17)E6410

PubMed: 32899202 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-00504-4

PubMed: 32855528 ( click the link to review the publication )

Dev Biol, 2020, 457(1):128-139

PubMed: 31550483 ( click the link to review the publication )

Cancer Med, 2020, 10.1002/cam4.2873

PubMed: 32030915 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2610-2620

PubMed: 33125122 ( click the link to review the publication )

Neural Plast, 2020, 2020:8815195

PubMed: 32802036 ( click the link to review the publication )

Front Pharmacol, 2020, 11:204

PubMed: 32194421 ( click the link to review the publication )

Dev Cell, 2019, 51(6):665-674.e6

PubMed: 31813796 ( click the link to review the publication )

J Cell Biol, 2019, 218(9):3134-3152

PubMed: 31371388 ( click the link to review the publication )

Elife, 2019, 8e50208

PubMed: 31482846 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31658643 ( click the link to review the publication )

Hum Mol Genet, 2019, 28(6):896-911

PubMed: 30445456 ( click the link to review the publication )

J Cell Physiol, 2019, 234(3):2058-2066

PubMed: 30317648 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(8)E1991

PubMed: 31018557 ( click the link to review the publication )

J Cell Biochem, 2019, 120(11):18979-18994

PubMed: 31245876 ( click the link to review the publication )

J Cell Biochem, 2019, 120(4):5386-5395

PubMed: 30367510 ( click the link to review the publication )

Exp Cell Res, 2019, 385(2):111671

PubMed: 31634481 ( click the link to review the publication )

Basic Clin Pharmacol Toxicol, 2019, 124(6):660-669

PubMed: 30548093 ( click the link to review the publication )

Hepatobiliary Pancreat Dis Int, 2019, 18(1):38-47

PubMed: 30243878 ( click the link to review the publication )

Phytomedicine, 2019, 67:153163

PubMed: 31901891 ( click the link to review the publication )

Neuron, 2018, 97(6):1235-1243

PubMed: 29526553 ( click the link to review the publication )

EMBO Rep, 2018, 19(2):269-289

PubMed: 29263200 ( click the link to review the publication )

Elife, 2018, 7

PubMed: 30014845 ( click the link to review the publication )

Lab Chip, 2018, 18(20):3184-3195

PubMed: 30204194 ( click the link to review the publication )
Exp Cell Res, 2018, 366(1):63-70

PubMed: 29548749 ( click the link to review the publication )

Mol Pain, 2018, 14:1744806918767560

PubMed: 29607715 ( click the link to review the publication )

Biol Reprod, 2018, 98(4):480-490

PubMed: 29329377 ( click the link to review the publication )

Oncol Rep, 2018, 39(1):21-30

PubMed: 29115520 ( click the link to review the publication )

Cell Transplant, 2018, 27(3):393-406

PubMed: 29749250 ( click the link to review the publication )

Anticancer Drugs, 2018, 29(10):995-1003

PubMed: 30106753 ( click the link to review the publication )

Int J Clin Exp Pathol, 2018, 11(5):2920-2930

PubMed: 31938417 ( click the link to review the publication )

Nat Commun, 2017, 8:14382

PubMed: 28176763 ( click the link to review the publication )

PLoS Genet, 2017, 13(8):e1006951

PubMed: 28797033 ( click the link to review the publication )

Cancer Discov, 2017,

PubMed: 28923910 ( click the link to review the publication )

Front Immunol, 2017, 9:2847

PubMed: 30568656 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(5):1813-1828

PubMed: 29065414 ( click the link to review the publication )

J Cell Mol Med, 2017, 21(3):568-578

PubMed: 27709831 ( click the link to review the publication )

Exp Cell Res, 2017, 357(1):79-87

PubMed: 28461158 ( click the link to review the publication )

Int J Biochem Cell Biol, 2017, 89:147-156

PubMed: 28624529 ( click the link to review the publication )

Mol Immunol, 2017, 92:68-75

PubMed: 29054053 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:5605-5619

PubMed: 29200875 ( click the link to review the publication )

Oncotarget, 2017, 8(26):42495-42509

PubMed: 28477008 ( click the link to review the publication )

EMBO Rep, 2016, 17(5):682-94

PubMed: 27113760 ( click the link to review the publication )

J Med Chem, 2016, 59(24):11050-11068

PubMed: 27736063 ( click the link to review the publication )

Cell Biosci, 2016, 10.1186/s13578-016-0104-8

PubMed: 27313840 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6626-38

PubMed: 26675547 ( click the link to review the publication )

J Hematol Oncol, 2015, 8:63

PubMed: 26048374 ( click the link to review the publication )

Development, 2015, 142(15):2610-22

PubMed: 26116667 ( click the link to review the publication )
Am J Cancer Res, 2015, 5(9):2569-89

PubMed: 26609469 ( click the link to review the publication )

Mol Carcinog, 2015, 10.1002/mc.22300

PubMed: 25728352 ( click the link to review the publication )

Int J Mol Med, 2015, 35(6):1641-50

PubMed: 25872645 ( click the link to review the publication )

Data Brief, 2015, 4:22-31

PubMed: 26217756 ( click the link to review the publication )

Stem Cell Reports, 2015, 5(5):816-828

PubMed: 26527387 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(5):544-59

PubMed: 24553082 ( click the link to review the publication )

Eur J Pharmacol, 2014, 10.1016/j.ejphar.2014.01.074

PubMed: 24534491 ( click the link to review the publication )

Mol Cell Biochem, 2014, 396(1-2):257-68

PubMed: 25064451 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbadis.2014.10.001

PubMed: 25305367 ( click the link to review the publication )

Insect Sci, 2014, 10.1111/1744-7917

PubMed: 25154865 ( click the link to review the publication )

Dev Biol, 2013, 381(2):312-23

PubMed: 23872235 ( click the link to review the publication )

Dev Cell, 2013, 25(2):169-81

PubMed: 23602386 ( click the link to review the publication )

Mol Cancer, 2013, 12:66

PubMed: 23786654 ( click the link to review the publication )

J Exp Clin Cancer Res, 2013, 5;32(1):7

PubMed: 23379358 ( click the link to review the publication )

Toxicol Lett, 2013, 225(2):318-324

PubMed: 24388991 ( click the link to review the publication )

PLoS One, 2013, 8(3):e57346

PubMed: 23483902 ( click the link to review the publication )

Liver Int, 2013, 33(1):149-61

PubMed: 23121638 ( click the link to review the publication )

Oncotarget, 2013, 4(10):1698-1711

PubMed: 24091605 ( click the link to review the publication )

Neuro Oncol, 2012, 14(12):1441-51

PubMed: 23104476 ( click the link to review the publication )

Cancer Res, 2012, 72(9):2262-74

PubMed: 22396494 ( click the link to review the publication )

Cancer Lett, 2012, 322(2):169-76

PubMed: 22450749 ( click the link to review the publication )

Exp Hematol, 2012, 40(5):418-27

PubMed: 22240607 ( click the link to review the publication )

产品安全说明书

Hedgehog/Smoothened抑制剂选择性比较

生物活性

产品描述

Cyclopamine (11-deoxojervine)是一种特异性Hedgehog (Hh)信号通路拮抗剂，作用于Smoothened (Smo)，在TM3Hh12细胞中IC50为46 nM。

靶点

Smoothened ^[1]
(TM3Hh12 cells)

46 nM

体外研究

Cyclopamine 抑制Hedgehog信号通路， IC50 为46 nM, 且在[3H]Hh-Ag结合实验中，作用于CHO-K1细胞，抑制人类Smo受体活性，IC50为 280 nM。^[1] Cyclopamine作用于表达Patched (PTCH) mRNA的肠源性肿瘤细胞，显著抑制 Hedgehog通路活性，这种作用存在剂量依赖性，且浓度为3 μM时，抑制肿瘤细胞生长，抑制达75-95%, 但是作用于不表达PTCH mRNA的结肠癌细胞没有效果，说明Cyclopamine 特定作用于Hedgehog 通路，且没有毒性。^[2]通过与Smo直接作用而抑制Hedgehog信号，Cyclopamine (10 μM) 抑制SMOhigh Cyclopamine-反应细胞系L3.6sl和 Panc 05.04增殖，抑制达 75-80%,且使凋亡率提高2.5到 3.5倍，但是不影响BxPC3-SMOlow 细胞系。^[3] Cyclopamine 处理E3LZ10.7细胞系，显著降低Snail mRNA，且提供E-钙粘着蛋白转录。Cyclopamine处理Hedgehog依赖型 L3.6pl 细胞，显著抑制浸润型细胞, 使转移细胞降低500多倍，但是对Hedgehog非依赖性细胞系Panc-1没有影响。^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
OS-RC-2	NXHKfIFsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Ml76TWM2OD13Lki2OlYh\|ryP	MlHlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
DOHH-2	Mo\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mlj3TWM2OD17LkO1Olg6KM7:TR?=	M2WzSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
no-10	M2rsTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmLZTWM2OD17LkmwN\|kh\|ryP	M3zKNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
LS-513	NXm3SGF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mof4TWM2OD1zMT6zOVQ4KM7:TR?=	NX7icVRxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
ALL-PO	NUXZZlltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NX3wV5dLUUN3ME2xNU44PzN2IN88US=>	MlX2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
8-MG-BA	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Ml\ITWM2OD1zMz6xNVI{KM7:TR?=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
RPMI-8402	Mmn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFfiVmVKSzVyPUG1Mlg2OzdizszN	NHi1dpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
EoL-1-cell	NVjEZ2pDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NEe2NWNKSzVyPUG4MlU6PDhizszN	NXHTTplxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
NALM-6	NH72TnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MlvUTWM2OD1zOT6wNVY4KM7:TR?=	MkXhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
DEL	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MoD3TWM2OD1{MD6xOFcyKM7:TR?=	MoPqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
SR	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NIXDbFVKSzVyPUKzMlY4OTVizszN	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
697	M1XST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mm\4TWM2OD1{Nj62NVU2KM7:TR?=	NEPNbIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
COLO-829	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1PZS2lEPTB;Mk[uPFQ5OyEQvF2=	Ml7MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
EVSA-T	NXTHeZl{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4nMT2lEPTB;MkeuOVU3OSEQvF2=	NID6fYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
ATN-1	NUnJRm5[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MmPLTWM2OD1\|MT6yN\|I6KM7:TR?=	NULI[nZ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
L-363	Mk[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MWfJR\|UxRTNzLke0OlEh\|ryP	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
LAMA-84	NI\0RXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIr3VGVKSzVyPUOyMlUzOTFizszN	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
NOS-1	NHy4cZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MkPXTWM2OD1\|ND6yPVU3KM7:TR?=	NX3YclZJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
BB30-HNC	NUDJeoZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFW4TWNKSzVyPUO0MlM{ODZizszN	NEXpXWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
BC-1	NHzoeGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVXJR\|UxRTN5Lkm3OFYh\|ryP	NVe2[3N{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
IST-SL2	NVrvNlYxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVLmdWJvUUN3ME2zPE4zOjRizszN	NHXiO409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
D-392MG	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NEHyc4pKSzVyPUSwMlIzOTVizszN	M13QT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
no-11	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3f1eGlEPTB;NECuOVUzOSEQvF2=	NU\QU4F1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
LC4-1	Mnn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Ml;PTWM2OD12MD64O\|E3KM7:TR?=	Mn7yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
A388	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVrJR\|UxRTR{LkW4OFgh\|ryP	MmDGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
NTERA-S-cl-D1	Mn\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NF[1PJRKSzVyPUSyMlcxPzRizszN	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
CESS	NULPPXJoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MnHXTWM2OD12ND6yNlMzKM7:TR?=	NYH6UFMxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
RS4-11	M3P2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M17vcWlEPTB;NEmuNFk{QCEQvF2=	Mli4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
MS-1	NFfDTZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2LVS2lEPTB;NUCuPVM2OSEQvF2=	M{\0bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
CTV-1	M4LuOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmDpTWM2OD13MT6wO\|Qh\|ryP	NF3ZPWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
D-502MG	NVf1Vm5qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVT3TZp5UUN3ME21NU43OjdzIN88US=>	NYOzPHBERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
ML-2	NHfDc3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1jLXWlEPTB;NUKuPVE6PSEQvF2=	M37XfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
SK-NEP-1	NGf5NopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGfYPFdKSzVyPUWzMlM6OjNizszN	MljqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
LOXIMVI	MnzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NU[xWWpuUUN3ME21N{42QDh2IN88US=>	NH22NYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
DJM-1	M2C0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MWrJR\|UxRTV4LkOzPVEh\|ryP	NGTJRVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
GI-1	NWDOUWdTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MnjoTWM2OD13Nj62NVQ6KM7:TR?=	MlHTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
IST-MES1	M{fvNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NEHMXXpKSzVyPU[wMlU1QTNizszN	M2XBcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
MV-4-11	M2O0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mnu0TWM2OD14MD62OVM5KM7:TR?=	NUf5XIpTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
OVCAR-4	NUezO\|VET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NIHZT2hKSzVyPU[zMlU3PTdizszN	M1HUclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
KE-37	M3PTN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MlW4TWM2OD14Nj6yOlY5KM7:TR?=	M13NS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
D-542MG	M{n3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3PQVWlEPTB;NkiuOFE{PSEQvF2=	NFraPWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
MHH-PREB-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFi2ZYJKSzVyPUeyMlg1PDFizszN	M1z2fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
MRK-nu-1	NF;5RlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2\MeWlEPTB;N{OuOFcxPSEQvF2=	NWXFPHJ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
D-247MG	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NG\N[ItKSzVyPUezMlU1PDJizszN	MlzHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
OCI-AML2	NUeycWFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3TuRmlEPTB;N{[uPVM3QSEQvF2=	MlnZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
LP-1	NUj0bFYxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mk\QTWM2OD16Mj64O\|MyKM7:TR?=	Ml\1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
HCC1599	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NHq3NFNKSzVyPUi0MlI5OzdizszN	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
KARPAS-45	M{PiVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MYXJR\|UxRTh2Lk[5PVIh\|ryP	NYDVSpFJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
BE-13	M1XXcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NUnkbnBiUUN3ME25PU4xPDd5IN88US=>	NUDzcpdMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
GCIY	NWfpNJBLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYD1cY9yUUN3ME25PU4xQTV2IN88US=>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
BV-173	NHjVToNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXjJR\|UxRTFyMD6zNlUh\|ryP	NF;WV\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
LB2518-MEL	Mli0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4LS[2lEPTB;MUCwMlc5QSEQvF2=	M4\zRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
KS-1	NXWy[2tUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWHyU4VDUUN3ME2xNFEvPjN7IN88US=>	NWPrT3pqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
MOLT-16	M1rXbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4\j[WlEPTB;MUC0Mlk5PiEQvF2=	MmjVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
NCI-H1770	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmPLTWM2OD1zMEiuO\|g1KM7:TR?=	NVfaVmdCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
NCI-H82	NFrwT3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M37zVmlEPTB;MUGwMlk4PiEQvF2=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
NCCIT	NVPq[lA3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVHJR\|UxRTFzMj61Nlkh\|ryP	M3vQOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
KALS-1	NF7uS4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NEXqN\|BKSzVyPUGxOU46PDFizszN	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
LB2241-RCC	NX;Pd\|UxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NETUXFZKSzVyPUGxOk43PzlizszN	Ml3yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
HH	NHHBcYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NEHPWJhKSzVyPUGxO{4{QTVizszN	M2HZ[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
HD-MY-Z	NIO1W\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NY\kVFdkUUN3ME2xNVgvPDh6IN88US=>	NWrWOXM5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
EB-3	NH7o[o1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVPJR\|UxRTF{Mz6wPVQh\|ryP	M2jyUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
BL-70	MoLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MoPiTWM2OD1zMkOuNVI4KM7:TR?=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
K-562	Mk\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXHJR\|UxRTF{Nj6yOFUh\|ryP	NUPjWVhPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
HT-144	NEi5fm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NV;nNJBjUUN3ME2xN\|MvOTZ2IN88US=>	NInmWIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
PF-382	NUHXVGZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NIXlfJpKSzVyPUGzOE4{PjFizszN	NVzjd5hmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
RPMI-8226	NEDabYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MWPJR\|UxRTF\|NT6wOFUh\|ryP	NH7VfIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
NCI-H1355	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Moj1TWM2OD1zM{WuOVg4KM7:TR?=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
LXF-289	NUjjXGhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M17FVmlEPTB;MUO5Mlc5OSEQvF2=	MljSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
NCI-H69	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MnmwTWM2OD1zNEKuPVMzKM7:TR?=	Ml7rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
SK-MEL-1	NYXkRYh7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NUL5[W4{UUN3ME2xOFcvOTNizszN	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
KARPAS-299	NU\wXYtnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NXfoWnRCUUN3ME2xOFkvOTJizszN	MmixQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
GB-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NIC0bYxKSzVyPUG0PU4{OjJizszN	NW[5[mxIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
CMK	MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MWXJR\|UxRTF2OT61NVUh\|ryP	NX7rVFQ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
MPP-89	MlXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NEi0PHBKSzVyPUG1Ok4xOzVizszN	NUfodJRJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
KU812	M2ezXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MlPlTWM2OD1zNkGuPVAzKM7:TR?=	NIXINIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
REH	MkXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NY\6UIR1UUN3ME2xOlIvOTJ3IN88US=>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
NEC8	NV32WHpXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MkHaTWM2OD1zNkWuNFI3KM7:TR?=	NG\UXI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
KP-N-YS	NH;LTpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVTJR\|UxRTF4OD6zPVUh\|ryP	M3WwOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
Ramos-2G6-4C10	M1vCWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{fVdmlEPTB;MU[5MlkyPSEQvF2=	M2j0ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
Becker	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlLYTWM2OD1zN{SuNVgh\|ryP	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
LB647-SCLC	NYnkOHhzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWS4OmVMUUN3ME2xO\|UvQDR3IN88US=>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
LU-139	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUnUcop3UUN3ME2xO\|gvODF7IN88US=>	MoLBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
QIMR-WIL	M{S5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MW\JR\|UxRTF5OT62OFYh\|ryP	NFf2cZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
NCI-H1395	NVfzb2FIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NW\3UJR[UUN3ME2xO\|kvQTl4IN88US=>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
NOMO-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NGrDSodKSzVyPUG4Nk45PSEQvF2=	M{m4NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
GI-ME-N	M1rOb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NV\zXnJnUUN3ME2xPFcvQTZ7IN88US=>	MoHwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
KMS-12-PE	NV7UdmVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3HqVmlEPTB;MUi5MlI4OyEQvF2=	NV\aO49kRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
Daudi	M3Hhdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mm\PTWM2OD1zOUGuNVI5KM7:TR?=	M4[zb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
LB996-RCC	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYLNN2hxUUN3ME2xPVEvPjl7IN88US=>	MlS5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
NCI-H2107	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYPNdGlkUUN3ME2xPVMvPzN7IN88US=>	MofpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
SK-PN-DW	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MYfJR\|UxRTF7ND63NVkh\|ryP	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
MC-CAR	M4HQUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYLxN4hJUUN3ME2yNFIvOjV\|IN88US=>	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
SNB75	M2\6UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NEXsW\|ZKSzVyPUKyNU46PCEQvF2=	MlfjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
ES4	MkfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Ml2xTWM2OD1{MkOuO\|g{KM7:TR?=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
KARPAS-422	NV\acXhpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3i0fWlEPTB;MkK4MlM2OiEQvF2=	M3j1bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
NCI-H1648	M3:we2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mnj3TWM2OD1{MkmuOFg6KM7:TR?=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
ES6	NGTWfYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{n4V2lEPTB;MkO5MlQ{KM7:TR?=	NYS2do5LRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
KNS-81-FD	NV\BWm85T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1PqcGlEPTB;MkSxMlE6PyEQvF2=	M1f4d\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
JAR	M4\pdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHfyV4pKSzVyPUK1Ok4zOjVizszN	NVnDV3BSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
NB1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUf6foxlUUN3ME2yOlAvPTF4IN88US=>	NGP5SXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
D-336MG	M3rwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MoTtTWM2OD1{NkCuOlk5KM7:TR?=	MmrFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
BC-3	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NV[2XYNUUUN3ME2yOlUvOTd6IN88US=>	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
HCC2218	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mon0TWM2OD1{Nk[uOFE2KM7:TR?=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
TE-9	NWjROZBMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHn0dlZKSzVyPUK2Ok43OjdizszN	Mm\zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
LB1047-RCC	MoLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NXzaTHB2UUN3ME2yOlYvPzV\|IN88US=>	M3zJZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
CTB-1	MoO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mlq1TWM2OD1{NkmuPVc{KM7:TR?=	M{i4S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
NB7	NFKwOGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NULWS44xUUN3ME2yO\|Eh\|ryP	NXrCXFJlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
ST486	NGXDbXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MYTJR\|UxRTJ5Nz60NVIh\|ryP	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
HCC1187	NHLCN5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MWrJR\|UxRTJ6Mj64NVEh\|ryP	NWixenl6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
NCI-SNU-16	M3;j[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4fMS2lEPTB;Mki0MlI1QCEQvF2=	M3vp[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
COR-L279	NF3Se49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2fk[WlEPTB;MkmxMlU5PCEQvF2=	NUXwTlNGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
ES8	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NIrLcYpKSzVyPUK5OE4yQDJizszN	MkL2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
U-698-M	MnT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVHJR\|UxRTJ7OD6yOFMh\|ryP	MojVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
HEL	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NH[1eJVKSzVyPUOwPU4yPDlizszN	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
KINGS-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MU\JR\|UxRTNzMD62O\|Qh\|ryP	MmnWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
KY821	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MUHJR\|UxRTN\|Nj61PVUh\|ryP	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
MZ1-PC	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVfJR\|UxRTN2NT62NVgh\|ryP	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
LS-411N	M2LQcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXLsNpRLUUN3ME2zOVQvPjZizszN	MnXBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
SIG-M5	MojsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NEjkSFJKSzVyPUO1PU44QDJizszN	NX\kRmdZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
HT	NXzKTGdvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MnfrTWM2OD1\|NkeuO\|EyKM7:TR?=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
HC-1	NVPkXZhGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Ml\XTWM2OD1\|NkeuO\|g4KM7:TR?=	M3LwZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
NCI-H1694	NXnORYg5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2Tr[GlEPTB;M{eyMlk{PCEQvF2=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
BB65-RCC	NWrCb5hTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MUHJR\|UxRTN5Nj6yOFUh\|ryP	MoTMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
HAL-01	NEDhZWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Moj1TWM2OD1\|N{muPFM5KM7:TR?=	NUPwSopYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
ARH-77	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NW\jTYtvUUN3ME2zPVQvODB6IN88US=>	NGLnS2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
MZ7-mel	M1i0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mo\jTWM2OD1\|OUeuNlM{KM7:TR?=	M4jTNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
SIMA	NWHEVXRyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NX3BWlNnUUN3ME20NFMvQTN\|IN88US=>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
DG-75	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWnLOYxQUUN3ME20NVUvPjl6IN88US=>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
HUTU-80	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MYTJR\|UxRTRzOT6xPFUh\|ryP	NHPKd\|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
KNS-42	NITuW25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NWPZ[FNyUUN3ME20NlUvQDF3IN88US=>	NUWwbnF3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
SH-4	M1jQXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2WyXGlEPTB;NEK3MlU3PSEQvF2=	NY\QfJdsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
L-540	M3jp[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MlS4TWM2OD12M{GuNFMyKM7:TR?=	MkHFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
NB10	NIDEfIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2e3V2lEPTB;NESxMlI{PCEQvF2=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
ES1	MnjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MkDSTWM2OD12NUKuO\|U{KM7:TR?=	M4TkWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
KMOE-2	NHnneXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4W2NGlEPTB;NEW2MlcyOSEQvF2=	M1rNV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
MC116	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVHJR\|UxRTR3OD6xNVYh\|ryP	M1L6fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
RCC10RGB	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NV\TPWtNUUN3ME20OlAvODB3IN88US=>	NUjrephzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
RL95-2	M2jxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NVPjPWd2UUN3ME20OlAvOjN5IN88US=>	NFTtRnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
Raji	M4XIWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NIf3XVRKSzVyPUS2PE4yPDNizszN	M2XDclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
CAS-1	NF7XfYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2ThRmlEPTB;NEeyMlA4OyEQvF2=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
Calu-6	Ml7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MkHuTWM2OD12N{WuNlY2KM7:TR?=	M1LSUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
KG-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVXJR\|UxRTR5OD60OEDPxE1?	NWT3cpo{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
LB771-HNC	M2jjSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M121cmlEPTB;NEiyMlI{OiEQvF2=	MlLCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
ACN	M1vjSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NV:yRoxKUUN3ME20PVMvPTl7IN88US=>	MmLSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
KM12	NIDLW2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MmS5TWM2OD12OU[uOVg6KM7:TR?=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
U2OS	NFvwfFNHfW6ldHnvckBie3OjeR?=			M2TCOWJqdmSrbnegZYZncW6rdImgeI8hf2muZDD0fZBmKFOvbzDlfJBz\XO\|ZXSgbY4hXTKRUzDj[YxteyCkeTDzZ4lvfGmubHH0bY9vKGOxdX70bY5oNCCNZDC9JFAvODF{NDFOwG0v	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB4M{WyNkc,OjNyNkO1NlI9N2F-
U2OS	NYG4UFdjTnWwY4Tpc44h[XO\|YYm=		MWOyJIhzew>?	MVPEbZNxdGGlZX3lcpQhd2ZiW{PIYYN6[2yxcHHtbY5mKG[{b32ge4lt\CC2eYDlJHNudyCneIDy[ZN{\WRiaX6gWVJQWyClZXzsd{Bi\nSncjCyJIhzeyCkeTDzZ4lvfGmubHH0bY9vKGOxdX70bY5oNCCNaTC9JFAvODF{NzFOwG0v	NIL2bmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C2N\|UzOid-MkOwOlM2OjJ:L3G+
TM3	M2C2SGZ2dmO2aX;uJIF{e2G7		MX[0PEBpenN?	MWLJcohq[mm2aX;uJI9nKEinZHflbI9oKHOrZ37hcIlv\yCyYYToe4F6KGmwIH3veZNmKFSPMzDj[YxteyCkZXHybY5oKHCWQT24fGdtcS2OdXOgdoVxd3K2ZYKgZ49ve3S{dXP0JIF{e2W\|c3XkJIF{KHS{YX7zZ5JqeHSrb37hcEBud2S3bHH0bY9vKG:oIFfsbUBi\nSncjC0PEBpenNiYomgcJVkcW[ncnHz[UBie3OjeTygTWM2OCB;IECuNFQ3KM7:TT6=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTB7MUW1PUc,OTlyOUG1OVk9N2F-
HCC827	NUHYfGp5TnWwY4Tpc44h[XO\|YYm=			M4XZZ2Rqe3CuYXPlcYVvfCCxZjDbN2heNWO7Y3zvdIFucW6nIH\yc40hW02RIG[0NFROKG23dHHueEBqdiCpZX\peIlvcWJicnXzbZN1[W62IHj1cYFvKEiFQ{iyO{Bk\WyuczDifUB{[2mwdHnscIF1cW:wIHPveY51cW6pLDDLbUA:KDBwMEWxJO69VS5?	M2n5RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{i3NVU3Lz5{OEe4O\|E2PjxxYU6=
HEK293	NGD4eYtHfW6ldHnvckBie3OjeR?=		NEDQUYUzKGi{cx?=	NXPlPFM3TGm\|cHzhZ4Vu\W62IH;mJGJQTEmSWT3sZYJmdGynZDDjfYNtd3CjbXnu[UBnem:vIHj1cYFvKFOvbzDy[YNmeHSxcjDlfJBz\XO\|ZXSgbY4hUEWNMkmzJINmdGy\|IHHmeIVzKDJiaILzJIJ6KG[udX;y[ZNk\W6lZTDtbYNzd3Olb4D5MEBKSzVyIE2gNE4xPjRizszNMi=>	MnvUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{Nki1OVEoRjJ{Mk[4OVUyRC:jPh?=
Shh Light2	MmjSSpVv[3Srb36gZZN{[Xl?		M4HJRVMxKGi{cx?=	NFPUVpJKdmirYnn0bY9vKG:oIHjl[IdmcG:pIIPp[45idGmwZzDwZZRpf2G7IHnuJI1wfXOnIGPobEBNcWeqdEKgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC\|b37pZ{Bp\WSpZXjv[{1qdmS3Y3XkJGdNUTFvbXXkbYF1\WRidILhcpNkemmydHnvcoFtKGGldHn2bZR6KG2nYYP1doVlKGGodHXyJFMxKGi{czDifUBlfWGuIHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhUUN3MDC9JFAvODd2MTFOwG0v	NFH0cWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{W2O\|M4OSd-Mke1Olc{PzF:L3G+
U2OS	NXz3coFlTnWwY4Tpc44h[XO\|YYm=			MVrCbY5lcW6pIHHm[olvcXS7IITvJHNudyCGNEezTEBufXSjboSg[ZhxemW\|c3XkJIlvKFV{T2OgZ4VtdHNiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiS3SgQUAxNjFzNjFOwG0v	MkixQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNkO1NlIoRjJ\|ME[zOVIzRC:jPh?=
DaOY	NVHBR5ZVTnWwY4Tpc44h[XO\|YYm=		NVf1WZVFPDhiaILz	Mn7UTY5pcWKrdHnvckBw\iCKZXTn[Yhw\yC\|aXfuZYxqdmdiaX6gbJVu[W5iRHHPXUBk\WyuczDhd5Nme3OnZDDhd{Bld3ewcnXneYxifGmxbjDv[kBIdGlzIH3SUmEh\XiycnXzd4lwdiCjZoTldkA1QCCqcoOgZpkhWlRvUFPSJIFv[Wy7c3nzMEBKSzVyIE2gNE4yPiEQvF2u	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEexOkc,OjR7MEC3NVY9N2F-
U2OS	NWTOO\|RvTnWwY4Tpc44h[XO\|YYm=		NWjJVY11OiCqcoO=	MnS1SIl{eGyjY3Xt[Y51KG:oIGuzTH1kgWOub4DhcYlv\SCocn;tJHNudyCGNEezTEBufXSjboSg[ZhxemW\|c3XkJIlvKFV{T2OgZ4VtdHNiYX\0[ZIhOiCqcoOgZpkhe2OrboTpcIxifGmxbjDjc5VvfGmwZzygT4khRSByLkKzNkDPxE1w	MlLMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNkO1NlIoRjJ\|ME[zOVIzRC:jPh?=
CHO	MoW2SpVv[3Srb36gZZN{[Xl?			M3n2PWFvfGGpb37pd5Qh[WO2aY\peJkh[XRiaIXtZY4hW22xIILlZ4VxfG:{IHX4dJJme3OnZDDpckBEUE9iY3XscJMh[nliW{PIYWhpNUGpIHLpcoRqdmdiYYPzZZktKEmFNUCgQUAxNjJ6IN88UU4>	M{nQXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEmxOVU6Lz5zOUC5NVU2QTxxYU6=
Shh Light2	MXnGeY5kfGmxbjDhd5NigQ>?		MlvqOFAhcHK\|	NGq2Z4tKdmirYnn0bY9vKG:oIGPITEBx[XSqd3H5JIlvKG2xdYPlJHNpcCCOaXfoeFIh[2WubIOgZYZ1\XJiNECgbJJ{KGK7IFfsbU1l\XCnbnTlcpQhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR\|UxKD1iMD6zJO69VS5?	M1jNR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNUmyO\|g5Lz5{MUW5Nlc5QDxxYU6=
Shh-light2	NGm4OIFHfW6ldHnvckBie3OjeR?=			M4Xz[2lvcGmkaYTpc44hd2ZiU33vMY1m\GmjdHXkJGhpKHOrZ37hcIlv\yCrbjDoeY1idiCVaHitcIlocHR{IHPlcIx{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhUUN3MDC9JFAvOyEQvF2u	NET1bm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK2PFU2OSd-MkKyOlg2PTF:L3G+
M210B4	MVzGeY5kfGmxbjDhd5NigQ>?		MV2yOEBpenN?	MUXJcohq[mm2aX;uJI9nKEinZHflbI9oKHOrZ37hcIlv\yCrbjDtc5V{\SCPMkGwRlQh[2WubIOgZZN{\XO\|ZXSgZZMh\G:5boLl[5Vt[XSrb36gc4YhWHSlaDDtVm5CKGW6cILld5Nqd25iYX\0[ZIhOjRiaILzJIJ6KFKWLWDDVkBidmGueYPpd{whUUN3MDC9JFAvPDNizszNMi=>	MlXEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC3NVYoRjJ2OUCwO\|E3RC:jPh?=
Shh-Light 2	M2nEW2Z2dmO2aX;uJIF{e2G7		NX;zVXdSOiCmYYnz	MmjURY51[WexbnnzeEBi[3Srdnn0fUBifCCVbX:gbY4hdW:3c3WgV4hpNUyrZ3j0JFIh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDTbIgucW6mdXPl[EBIdGlzLYLldI9zfGW{IHHjeIl3cXS7IHHmeIVzKDJiZHH5d{BjgSCmdXHsMYx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDt[ZRpd2RuIFnDOVAhRSByLkS4OEDPxE1w	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB4M{WyNkc,OjNyNkO1NlI9N2F-
Shh Light2	MVfGeY5kfGmxbjDhd5NigQ>?			Mlz3TY5pcWKrdHnvckBw\iCVSFigbY4hdW:3c3WgV4hpKEyrZ3j0NkBk\WyuczDifUBIVElvcnXzdI9ve2m4ZTDmbZJm\my7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3MDC9JFAvPSEQvF2u	NGrGdWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUOwPVA5OCd-MUmzNFkxQDB:L3G+
C3H10T1/2	MnrkSpVv[3Srb36gZZN{[Xl?			NUiwUXhNUW6qaXLpeIlwdiCxZjDOMZRmem2rbnHsJHNJUCCjY4TpeoF1\WRicHH0bJdigSCrbjDtc5V{\SCFM1ixNHQyNzJiY3XscJMh[XO\|ZYPz[YQh[XNiU1HHMYlv\HWlZXSgZ4VtdCCmaX\m[ZJmdnSrYYTpc44h[nliYXzrZYxqdmVicHjvd5Bp[XSjc3WgZZN{[XluIFnDOVAhRSByLk[g{txONg>?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTV7Mke4PEc,OjF3OUK3PFg9N2F-
C3H10T1/2	MnHHSpVv[3Srb36gZZN{[Xl?		Mmm2OkBpenN?	NGHOOopKdmirYnn0bY9vKG:oIGPBS{1qdmS3Y3XkJIRq\m[ncnXueIlifGmxbjDv[kBud3W\|ZTDt[ZNmdmOqeX3hcEBxdHW{aYDveIVvfCCFM1ixNHQyNzJiY3XscJMhfG9iYXzrZYxqdmVicHjvd5Bp[XSjc3WgdI9{cXSrdnWgc4V{\W:kbHHzeJMh[W[2ZYKgOkBpenNuIFnDOVAhRSByLk[yJO69VS5?	NFPQRnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK2PFU2OSd-MkKyOlg2PTF:L3G+
ASZ001	Mk[wSpVv[3Srb36gZZN{[Xl?		NV;hR\|hCPDhiaILz	M4G5fmlvcGmkaYTpc44hd2ZiSHXk[4Vpd2dic3nncoFtcW6pIHnuJI1wfXOnIFHTXlAxOSClZXzsd{Bie3Onc4Pl[EBieyCmb4fudoVofWyjdHnvckBw\iCJbHmxJI1TVkFiZYjwdoV{e2mxbjDh[pRmeiB2ODDodpMh[nliUmStVGNTKGGwYXz5d4l{NCCLQ{WwJF0hOC54NjFOwG0v	NXjXTYRqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA4OTZpPkK0PVAxPzF4PD;hQi=>
M210B4	M4TKdWZ2dmO2aX;uJIF{e2G7		MXmyOEBpenN?	NE\LUppKdmirYnn0bY9vKG:oIFjl[IdmcG:pIIPp[45idGmwZzDpckBud3W\|ZTDNNlExSjRiY3XscJMh[XO\|ZYPz[YQh[XNiZH;3cpJm\3WuYYTpc44hd2ZiR3zpNUBuWk6DIHX4dJJme3Orb36gZYZ1\XJiMkSgbJJ{KGK7IGLUMXBEWiCjbnHsfZNqeyxiSVO1NEA:KDBwODFOwG0v	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEexOkc,OjR7MEC3NVY9N2F-
medulloblastoma cells	MWfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			M{ize2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2VibXXkeYxtd2KuYYP0c41iKGOnbHzzJIhiemKxcnnu[{Bp\XSncn;6fYdwfXNicITjbFEh\2WwZTDifUBOXFRiYYPzZZktKEWFNUCgQUAyKM7:TT6=	MlrKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd2MUe2N\|EoRjF5NEG3OlMyRC:jPh?=
CHO	MYPGeY5kfGmxbjDhd5NigQ>?			NVfNc5BkSW62YXfvcol{fCCjY4Tpeol1gSCjdDDtc5V{\SCVbX:gdoVk\XC2b4Kg[ZhxemW\|c3XkJIlvKEOKTzDj[YxteyCkeTDbN2heUGhvQXegZolv\GmwZzDhd5NigSxiSVO1NEA:KDFwMjFOwG0v	MmrkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlyOUG1OVkoRjF7MEmxOVU6RC:jPh?=
Shh-Light2	MnnnSpVv[3Srb36gZZN{[Xl?		NWXoZZhvPDhiaILz	NXzub4tFUW6qaXLpeIlwdiCxZjDTTGghcW5ibX;1d4UhW2iqLVzp[4h1OiClZXzsd{Bi\nSncjC0PEBpenNiYomgS4xqOSC{ZYDvdpRmeiCpZX7lJIF{e2G7IHnuJJBz\XOnbnPlJI9nKFODRzygTWM2OCB;IEGuN\|EzKM7:TT6=	NH;sc\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUW0NVQ6OCd-MUm1OFE1QTB:L3G+
MEF	Mn;iSpVv[3Srb36gZZN{[Xl?			MYPJcohq[mm2aX;uJI9nKFOvbzDpckBud3W\|ZTDQeINpNWSnZnnjbYVvfCCPRV[gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCVaHitbY5lfWOnZDDHcIkyKHS{YX7zZ5JqeHSrb37hcEBi[3Srdnn0fUwhUUN3MDC9JFEvPSEQvF2u	NUDiSGpSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwO\|Q2PDFpPkKzNFc1PTRzPD;hQi=>
MEF	NVfQVW91TnWwY4Tpc44h[XO\|YYm=		MYWzNEBpenN?	NIX0XVVKdmirYnn0bY9vKG:oIGPtc{BqdiCvb4Xz[UBRfGOqLXTl[olkcWWwdDDNSWYh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDTbIgucW6mdXPl[EBIdGlvcnXzdI9ve2m4ZTDi[ZRi\2GuYXP0c5Nq\GG\|ZTDhZ5Rqfmm2eTDh[pRmeiB\|MDDodpMh[nliQnX0ZWdNdyCjc4PhfUwhUUN3MDC9JFEvQSEQvF2u	M1XhSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEe0OVQyLz5{M{C3OFU1OTxxYU6=
neural precursor cells	NFu5TZNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=			M1vIR2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2VibnX1doFtKHC{ZXP1dpNweiClZXzsd{BjgSClb3zvcpkh\m:{bXH0bY9vKGG\|c3H5MEBGSzVyIE2gNVMvPDRizszNMi=>	Mnr5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd2MUe2N\|EoRjF5NEG3OlMyRC:jPh?=
U87	NIfsR3JEgXSxdH;4bYNqfHliYYPzZZk>			MkPoR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWVg4KGOnbHzzJIF{e2W\|c3XkJIF{KH[rYXLpcIl1gSCrbjDwdoV{\W6lZTDv[kBj\XSjIHfseYN2em:waXThd4UtKEmFNUCgQUAyPS53IN88UU4>	NETncWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEGxOlkxPCd-MkCxNVY6ODR:L3G+
U87MG	M2rjcmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NF7GO5U4OiCqcoO=	MXPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFV6N13HJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFnDOVAhRSB{Mj61JO69VS5?	NHLabFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKyOlY2Pyd-MkKyNlY3PTd:L3G+
A549	NGXFfJpCdnSrY3HuZ4VzKGG\|c3H5			NIjKW\|RCdnSrY3HuZ4VzKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{BjgSCPVGOgZZN{[XluIFnDOVAhRSB2OTFOwG0v	NWTnV2M2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyNlE5PzJpPkG4NlIyQDd{PD;hQi=>
DU145	MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NUjJeINsPSC3TR?=	M{XyR\|k3KGi{cx?=	NXvTSlRVT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hTFVzNEWgZ4VtdHNiYYSgOUB2VSCjZoTldkA6PiCqcoO=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJ2OUGyOUc,OTh{NEmxNlU9N2F-
DU145	MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MlHqNVAhfU1?	M3nFZlk3KGi{cx?=	NXWzdodlT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hTFVzNEWgZ4VtdHNiYYSgNVAhfU1iYX\0[ZIhQTZiaILz	MmfNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{NEmxNlUoRjF6MkS5NVI2RC:jPh?=
HEK293	NGPPeGNHfW6ldHnvckBie3OjeR?=			NVfYVW84UW6qaXLpeIlwdiCxZjDi[ZRiKGejbHHjeI9{cWSjc3WgbY4hUEWNMkmzJINmdGy\|	NILoSWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{S5OFc3Pid-MUe0PVQ4PjZ:L3G+
22Rv	MmPiSpVv[3Srb36gZZN{[Xl?			MkW1VoVlfWO2aX;uJI9nKGW6cILld5Nqd25ib3[gVHREUCCvUl7BJIlvKGi3bXHuJFIzWnZiY3XscJM>	M1Tqb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NEm0O\|Y3Lz5zN{S5OFc3PjxxYU6=
PANC1	NF\Ic\|JHfW6ldHnvckBie3OjeR?=	NHPZ[GQxNjJidV2=	M{\yelI1KGi{cx?=	MYfJcohq[mm2aX;uJI9nKEiqL1fMTVEudWWmaXH0[YQhWFSFSDDtVm5CKGW6cILld5Nqd25iaX6gbJVu[W5iUFHOR\|Eh[2WubIOgZZQhOC5{IIXNJIFnfGW{IEK0JIhzeyCkeTDSWE1RS1J?	M2nTclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNEWwNVcxLz5{MES1NFE4ODxxYU6=
PANC1	NVX3b2g4TnWwY4Tpc44h[XO\|YYm=	MUSwMlQhfU1?	NFiyT4czPCCqcoO=	NWnMSoRYUW6qaXLpeIlwdiCxZjDIbE9IVElzLX3l[IlifGWmIGDUR2ghdVKQQTDlfJBz\XO\|aX;uJIlvKGi3bXHuJHBCVkNzIHPlcIx{KGG2IECuOEB2VSCjZoTldkAzPCCqcoOgZpkhWlRvUFPS	NE[3SIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MES1NFE4OCd-MkC0OVAyPzB:L3G+
Shh Light2	NUD2[Wd2TnWwY4Tpc44h[XO\|YYm=	NHvnSJc3NjJ3IIXN	Mki0N\|AhcHK\|	MX\Jcohq[mm2aX;uJI9nKE5vcHHscYl1d3muYYTl[EBUcGhiaX6gcY92e2ViU3joJGxq\2i2MjDj[YxteyCjdDC2MlI2KHWPIHHmeIVzKDNyIHjyd{BjgSCoaYLl[ox6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeR?=	M{TwOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUWxO\|MyLz5zOUG1NVc{OTxxYU6=
U87MG	MorCSpVv[3Srb36gZZN{[Xl?	M{TzNVExKHWP	NYjPbWFPPCCqcoO=	MX;Jcohq[mm2aX;uJI9nKEinZHflbI9oKHOrZ37hcIlv\yCyYYToe4F6KGmwIHj1cYFvKFV6N13HJINmdGy\|IHHzd4V{e2WmIHHzJIRwf25icnXneYxifGmxbjDv[kBIdGlzIHH0JFExKHWPIHHmeIVzKDRiaILzJIJ6KFKWLWDDVkBidmGueYPpdy=>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ{Nk[1O{c,OjJ{Mk[2OVc9N2F-
HEK293	NED4bVNHfW6ldHnvckBie3OjeR?=	M4H0dFUhfU1?	MnPCNVAhcHK\|	M1v0TGRqe3CuYXPlcYVvfCCxZjDCU2RKWFlvY4njcI9x[W2rbnWg[pJwdSCqdX3hckBUdW9iZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCjdDC1JJVOKG2nYYP1doVlKGGodHXyJFExKGi{czDifUBFSVCLIIP0ZYlvcW6pIHLhd4VlKG[udX;y[ZNk\W6lZTDtbYNzd3Olb4DpZ{Bie3OjeR?=	MnzmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5M{[wOlMoRjJ5N{O2NFY{RC:jPh?=
HEK293	NIX5[YtHfW6ldHnvckBie3OjeR?=	M3PJNVUhfU1?	MXKxNEBpenN?	NWT4dVBzTGm\|cHzhZ4Vu\W62IH;mJGJQTEmSWT3jfYNtd3CjbXnu[UBnem:vIHj1cYFvKFOvbzDlfJBz\XO\|ZXSgbY4hUEWNMkmzJINmdGy\|IHH0JFUhfU1ibXXhd5Vz\WRiYX\0[ZIhOTBiaILzJIJ6KE[DQ2OgZY5idHm\|aYO=	NYHkNFdMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3N\|YxPjNpPkK3O\|M3ODZ\|PD;hQi=>
C3H10T1/2	MUDGeY5kfGmxbjDhd5NigQ>?	Mn\3OVUvPSC2bzC0OVAxKG6P		NYnxVnM{S2:vcHX0bZRqfmViaX7obYJqfGmxbjDv[kBUdW9iaX6gcY92e2ViQ{PINVBVOS9{IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhW0GJLXnu[JVk\WRiR3zpNUB1emGwc3PybZB1cW:wYXygZYN1cX[rdImgZZQhPTVwNTD0c{A1PTByIH7NJIJ6KHGSQ2KgZY5idHm\|aYO=	M{PSN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEe0OVQyLz5{M{C3OFU1OTxxYU6=
U2OS	NWHp[ph[TnWwY4Tpc44h[XO\|YYm=	MVe1JJVO	MlfjOkBpenN?	NWSxeYl7SW62YXfvcol{fCCjY4Tpeol1gSCjdDDjbIlu\XKrYzDTcY8hPjN\|IH31eIFvfCCneIDy[ZN{\WRiaX6gWVJQWyClZXzsd{Bkd2W6cILld5NqdmdiYnX0ZUBienKnc4TpclIuT0[SIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiaX70doFk\WyudXzhdkBj\XSjIHHydoV{fGmwMj3HSnAh[WepcnXnZZRmKG[xcn3heIlwdiCjdDC1JJVOKGGodHXyJFYhcHK\|IHL5JINwdm[xY3HsJI1q[3Kxc3PvdJk>	M{LMO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|ME[zOVIzLz5{M{C2N\|UzOjxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Snail / E-cadherin / Slug / Vimentin ; PubMed: 26859575 Oncotarget SW1736 and WRO82 cells were incubated in the presence of vehicle (0.5% DMSO) or the indicated concentrations of cyclopamine or GANT61 for 72 hr. The cells were harvested and analyzed for the expression of several genes involved in EMT. Gli1 / TGF-β1 / CXCR4; PubMed: 26137001 Oncol Lett Western blotting demonstrated that Gli1, TGF-β1 and CXCR4 protein expression levels were downregulated in the AGS cells treated with cyclopamine for 24 h. NF-κB / Cyclin D1 / MMP2 / MMP9; PubMed: 23599805 Oncol Lett Whole cell lysates were prepared, and 50 μg proteins were resolved using SDS-PAGE, followed by immunoblotting with the indicated specific antibodies against NF-κB, cyclin D1, MMP2 and MMP9.	26859575 26137001 23599805
Immunofluorescence	PCNA / β-catenin; PubMed: 28747625 Sci Rep Immunofluorescence images demonstrating the distribution of PCNA or β-catenin in EH cells pre-treated with cyclopamine in presence and absence of estrogen for 24 h. Experiments were repeated at least three times. Vimentin; PubMed: 24553082 Cancer Biol Ther Vimentin protein expression was reduced following treatment with cyclopamine (20 μmol/L; 72 h), detected by immunocytochemistry.	28747625 24553082

体内研究

Cyclopamine 每天按50 mg/kg剂量处理小鼠，持续22天，消除HUCCT1移植瘤，且没有明显副作用。^[2] Cyclopamine 按1.2 mg剂量处理Panc 05.04和 L3.6sl驱动的肿瘤7天，前者诱导明显的肿瘤细胞凋亡，后者降低肿瘤质量，降低达50-60%，但是作用于BxPC3-SMOlow肿瘤没有效果。^[3] Cyclopamine单独处理E3LZ10.7 和L3.6pl移植瘤，显著抑制肿瘤转移，且和 Gemcitabine联用处理，完全废除转移。^[4]

激酶实验：^[1]	- 合并激酶实验: Gli-Luc实验测定Hh 信号通路末期, 即使用荧光素酶进行读数，测定Gli的转录调控。Cyclopamine 在DMSO中连续稀释用于实验，然后加到空的实验板上。TM3Hh12 细胞(TM3 细胞含Hh反应受体基因结构 pTA-8xGli-Luc) 悬浮在含5% FBS 和15 mM Hepes pH 7.3的F12 Ham’s/DMEM (1:1)培养基上, 加到实验板上，与Cyclopamine在37^oC下温育30分钟左右。1 nM Hh-Ag 1.5 加到实验板上，然后在37^oC下温育。48小时后，在实验板中加入Bright-Glo或MTS，然后在492 nm处测定发光度或吸光度。通过分析反应曲线，使用R统计软件包测定IC50值。
细胞实验：^[2]	- 合并 Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, 和HCT116 Concentrations: 溶于DMSO, 终浓度为3 μM Incubation Time: 4天 Method: 在96孔板上，用Cyclopamine 处理细胞。通过MTS实验测定细胞活力。进行CellTiter96比色测定，进行2和4天，然后在490 nm处通过测定光密度而测定存活细胞。 (Only for Reference)
动物实验：^[2]	- 合并 Animal Models: 皮下注射HUCCT1细胞的无胸腺裸鼠 Dosages: 50 mg/kg/day Administration: 皮下注射处理 (Only for Reference)

参考文献

[4] Feldmann G, et al. Cancer Res, 2007, 67(5), 2187-2196.

- 合并

溶解度 (25°C)

体外	DMF	10 mg/mL warmed (24.29 mM)
	Ethanol	2 mg/mL warmed (4.85 mM)
	DMSO	Insoluble

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Cyclopamine SDF

分子量	411.62
化学式	C₂₇H₄₁NO₂
CAS号	4449-51-8
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	11-deoxojervine

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
How to reconstitute the compound for in vivo use in mice?
回答：
One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

用于临床的Smoothened抑制剂

LDE225 (NVP-LDE225,Erismodegib) : Phase III for Hh-pathway activated relapsed Medulloblastoma (MB).
最新的Smoothened抑制剂

GANT61 : Inhibitor for GLI1 as well as GLI2-induced transcription, inhibits hedgehog with IC50 of 5 μM, displays selectivity over other pathways, such as TNF and glucocorticoid receptor gene transactivation.
Smoothened激活剂

Purmorphamine : Directly binds and activates Smoothened, and blocks BODIPY-cyclopamine binding to Smo with IC50 of ~ 1.5 μM.

研究领域

产品类型

定制您的化合物库

Cyclopamine

客户使用Selleck生产的Cyclopamine发表文献94篇：

产品安全说明书

Hedgehog/Smoothened抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Cyclopamine SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

常见问题及建议解决方法

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

相关Hedgehog/Smoothened产品